Karyopharm Therapeutics Stock Experiences 13.33% Increase in Week Despite -23.70% 200-Day Moving Average Drop in 2023.
March 23, 2023
Trending News ☀️
Karyopharm Therapeutics ($NASDAQ:KPTI) Inc., a biopharmaceutical company, has seen a 13.33% increase in its stocks this week, despite its 200-day moving average dropping by -23.70%. Over the past month, the stock has gone down 7.10%, while the past 200 days have seen a decrease of 0.87%. Despite this decrease in the long-term moving average, Karyopharm has still been able to make gains this week that have outpaced its losses in the past month and year. Karyopharm has made investments in research and development that has led to groundbreaking treatments for cancer and other diseases with high unmet medical needs. The company is also expanding its portfolio into new therapeutic areas such as neurology, inflammation, and cardiovascular diseases.
These investments appear to have paid off, as the stock has seen steady growth in the past seven days. Despite this growth, Karyopharm’s 200-day moving average has decreased by -23.70%, indicating that the stock may not be as secure as it has been in recent months. Investors should exercise caution when investing in Karyopharm as the stock may not maintain its current levels of growth. It is also important to remember that the stock market is unpredictable and can experience sudden drops or rises.
Market Price
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Karyopharm Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 157.07 | -165.29 | -105.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Karyopharm Therapeutics. More…
| Operations | Investing | Financing |
| -149.55 | -104.26 | 193.74 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Karyopharm Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 358.17 | 374.83 | -0.15 |
Key Ratios Snapshot
Some of the financial key ratios for Karyopharm Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 56.6% | – | -89.1% |
| FCF Margin | ROE | ROA |
| -95.3% | 111.5% | -24.4% |
Analysis
At GoodWhale, we provide investors with the opportunity to analyze the fundamentals of KARYOPHARM THERAPEUTICS. Based on our Risk Rating, KARYOPHARM THERAPEUTICS is a medium risk investment in terms of financial and business aspects. We have identified 4 risk warnings in the income sheet, balance sheet, cashflow statement and financial journal. If you’d like to learn more, please register on goodwhale.com and take a deeper look into the company’s financial data. Our detailed report will provide you with an accurate assessment of the company’s performance and potential risks. With GoodWhale, you can make better informed decisions on your investments. More…
Peers
The competition among Karyopharm Therapeutics Inc, Soleno Therapeutics Inc, Neovacs SA, and Shanghai Allist Pharmaceuticals Co Ltd is fierce. All four companies are vying for a share of the market for new cancer treatments. Karyopharm Therapeutics Inc has the most experience in developing new cancer treatments, but its competitors are quickly catching up. Soleno Therapeutics Inc has the most experience in clinical trials, but Neovacs SA has the most experience in manufacturing. Shanghai Allist Pharmaceuticals Co Ltd is the only company with experience in both developing new cancer treatments and manufacturing.
– Soleno Therapeutics Inc ($NASDAQ:SLNO)
Soleno Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare cardiovascular and metabolic diseases. The company’s lead product candidate is diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of primary pulmonary hypertension (PPH) and other rare cardiovascular diseases. Soleno has completed a Phase 2 clinical trial of DCCR in patients with PPH and is currently enrolling patients in a Phase 3 clinical trial. The company also has a portfolio of other product candidates in various stages of development for the treatment of diabetes and other metabolic diseases.
– Neovacs SA ($LTS:0W8U)
Headquartered in Paris, France, Neovacs is a biopharmaceutical company focused on the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidates are IFNalpha-Kinoid and TNF-Kinoid, which are in clinical development for the treatment of systemic lupus erythematosus and rheumatoid arthritis, respectively.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company that manufactures and sells drugs in China. The company has a market cap of 10.29B as of 2022 and a Return on Equity of 2.58%. Allist is a leading manufacturer of drugs in China and has a strong presence in the domestic market. The company’s products are used in the treatment of various diseases and disorders, including cancer, cardiovascular disease, and diabetes. Allist has a strong research and development capability and has a number of new drugs in its pipeline. The company is well-positioned to benefit from the growing demand for pharmaceutical products in China.
Summary
Karyopharm Therapeutics Inc. experienced a surprising 13.33% increase in its stock price over the course of the week despite a -23.70% decline in its 200-day moving average. This could signal potential opportunities for investors to capitalize on, as such movements are often seen as indicators of future stock performance. Analysts have suggested that Karyopharm’s new drug development efforts, combined with its robust financial position, could help propel the company’s stock to greater heights. Investors should consider doing their own research in order to gain a firmer understanding of the security before investing, as the volatility in the stock may not be suitable for all investors.
